Phaseline

Companies › Oxford BioMedica

Oxford BioMedica: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RetinoStat
Adeno-associated virus (AAV) vector delivering soluble fms-like tyrosine kinase-1 (sFLT1)
SFLT1Phase 1Age-Related Macular DegenerationMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01678872RetinoStatPhase 1Age-Related Macular DegenerationOphthalmologyMar 2029

Targets

SFLT1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.